Company Research Report: Synergia Medical

Company Overview

• Name: Synergia Medical

• Mission: To transform patient care through the development of advanced optoelectronic medical devices, focusing on personalized neural stimulation systems and therapies.

• Founded: 2014

• Founders: Attila Borbath, Pascal Doguet

• Key People:

• Attila Borbath (Co-founder, CEO)

• Vincent De Rudder

• Gijs Klarenbeek

• Anne Renaud

• Dan Scherrer (COO)

• Board of Directors includes Sophie Baratte, Marc Nolet de Brauwere, Pierre Detrixhe, Attila Borbath, Denis Gestin, and Enrique Vega.

• Headquartered: Rue Emile Francqui 6 (4th floor), 1435 Mont-St-Guibert, Belgium

• Number of Employees: Nearly 20, as per the last update, operational since 2015

• Revenue: No information is available

• Known For: Developing innovative optoelectronic neurostimulators, particularly for the treatment of drug-resistant epilepsy using the NAO.VNS™ system.

Products

• NAO.VNS™

• Description: A pioneering optoelectronic neurostimulation device primarily used for the treatment of drug-resistant epilepsy through Vagus Nerve Stimulation (VNS).

• Key Features:

• Minimizes the use of metal by utilizing quartz and polymer optical fibers.

• Offers unconditional MRI compatibility.

• Enhanced cybersecurity through optical communication.

• Rechargeable battery and uses miniaturized photovoltaic cells.

• Collects patient data continuously for personalized treatment.

• Encourages development of future light-based therapies.

Recent Developments

• New Products/Product Launches:

• The NAO.VNS system has successfully been implanted in the first patients as part of the AURORA study, indicating a significant step in the treatment of drug-resistant epilepsy.

• New Features:

• The NAO.VNS system’s recent implantations highlight its compatibility with MRI and fMRI, providing enhanced personalization of treatments.

• Partnerships and Recognitions:

• Awarded the prestigious Prix Galien 2023 in Belgium for promising medical devices.

• Received a €2.5 million grant from the EIC Accelerator program in October 2022.

• Completed a successful €12.8 million Series B funding round, enabling preparations for clinical trials.

• Management and Operational Changes:

• Appointment of Dan Scherrer as COO in November 2022 to strengthen the management in product development and supply chain.

• Clinical and Regulatory Progress:

• Authorization was received from the Federal Agency for Medicines and Health Products (FAMHP) to carry out a first-in-human study for drug-resistant epilepsy.

• Planning a pivotal trial across Europe, USA, and Canada following the AURORA study’s successful completion.

These recent activities underscore Synergia Medical’s commitment to advancing the treatment of drug-resistant epilepsy and improving patients' quality of life through groundbreaking medical technology.